David Henry, MD, on Anticoagulants: Expert Perspective

2015 ASH Annual Meeting

David Henry, MD, of Pennsylvania Hospital, discusses new advances with direct oral anticoagulants, or DOACs.

David A. Williams, MD, on the Goals and Highlights of ASH 2015

Outgoing ASH President, David A. Williams, MD, of the Dana-Farber/Boston Children’s Hospital, gives an overview of this year’s Annual Meeting of the American Society of Hematology.

Lymphoma

Ronald Go, MD

Ronald Go, MD, on Survival in NHL and Treatment Facility Volume

Ronald Go, MD, of the Mayo Clinic, discusses a study that used the National Cancer Data Base to determine the extent to which the number of non-Hodgkin lymphoma patients treated annually in a facility affects overall survival (Abstract 266).

Lymphoma

John Leonard, MD

John Leonard, MD, on DLBCL: Results From the Pyramid Trial

John Leonard, MD, of Weill Cornell Medical College, discusses this phase II study of R-CHOP with or without bortezomib in patients with untreated non-germinal center B-cell-like subtype diffuse large cell lymphoma (Abstract 811).

Lymphoma

Simon Rule, MD

Simon Rule, MD, on MCL: Ibrutinib vs Temsirolimus

Simon Rule, MD, of Derriford Hospital, discusses results from an international, multicenter study in patients with previously treated mantle cell lymphoma (Abstract 469).

Lymphoma

Jonathon B. Cohen, MD

Jonathon Cohen, MD, on Deferring MCL Treatment

Jonathon B. Cohen, MD, of the Winship Cancer Institute, discusses a study that used the National Cancer Data Base to study the impact on overall survival of deferring treatment in patients with newly diagnosed mantle cell lymphoma (Abstract 2717).

Oct

Today In Oncology

David Henry, MD, on Anticoagulants: Expert Perspective

Related Videos

David A. Williams, MD, on the Goals and Highlights of ASH 2015

Ronald Go, MD, on Survival in NHL and Treatment Facility Volume

John Leonard, MD, on DLBCL: Results From the Pyramid Trial

Simon Rule, MD, on MCL: Ibrutinib vs Temsirolimus

Jonathon Cohen, MD, on Deferring MCL Treatment

Bivalent CAR T-Cell Therapy Shows No Delayed Toxicity and Promising Survival in Recurrent Glioblastoma

Claudia Henschke, PhD, MD Finding Lung Cancer in Time

Starting Surveillance Colonoscopy After High-Risk Adenoma Removal When Is the Right Time

Evolving Strategies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

AI Model Based on Facial Image Analysis Estimates Biological Age and Mortality Risk in Patients With Cancer